National
Two gay candidates shine in fundraising
Pougnet, Cicilline post strong second-quarter results
Congressional candidate David Cicilline, the mayor of Providence, R.I., has raised $1.16 million over the course of his campaign. (Photo courtesy of Cicilline)
Two gay politicians posted strong second-quarter fundraising numbers that could propel them to seats in Congress.
Campaign finance reports made public earlier this month show Steve Pougnet, the mayor of Palm Springs, Calif., and David Cicilline, the mayor of Providence, R.I., boasting particularly strong numbers.
And Pougnet had the added accomplishment of keeping his fundraising numbers on par with his incumbent Republican opponent, Rep. Mary Bono Mack (R-Calif.). Both candidates raised about $400,000 for the April to June period.
The second-quarter numbers mean Pougnet has raised $1,267,910 so far in his campaign, leaving him with $878,283 in cash on hand, while Bono Mack raised $1,731,752, leaving her with $1,241,919 in cash on hand.
In a statement, Pougnet said he’s “incredibly humbled” by the support he’s received in his bid to represent California’s 45th congressional district.
“In these very difficult times, our congresswoman has been absent and it’s clear people are hungry for change,” Pougnet added.
But Ryan Mahoney, campaign manager for Bono Mack, touted the Republican candidate’s fundraising ability and noted that Bono Mack is “humbled” by the support she’s received.
“She is proud to represent the people of California’s 45th congressional district and will continue to fight on their behalf to end reckless spending and debt in Washington and create more jobs and better business opportunities in California,” Mahoney said.
Pougnet’s ability to match Bono Mack during the second quarter is unusual because challengers often do not match their incumbent opponents in fundraising. The fundraising numbers are also significant because the race in the 45th district is widely seen as among the most competitive congressional contests in the country.
The Democratic Congressional Campaign Committee put Pougnet on its “Red to Blue” program, and Bono Mack has been a lawmaker the National Republican Congressional Committee has worked to protect.
Notable donations to Pougnet from LGBT groups include $2,400 from the Gay & Lesbian Victory Fund and $6,900 from the Human Rights Campaign. Both organizations have endorsed the candidate. Donations also have come from Bruce Bastian, a Utah-based gay billionaire philanthropist, who donated $2,400; Hilary Rosen, a D.C. lesbian PR executive, who donated $1,000; and Lane Hudson, a D.C. gay activist, who contributed $300.
But Bono Mack is not without LGBT donors. In April, the Log Cabin Republicans gave $500 to her campaign.
Bono Mack had been considered a pro-LGBT Republican because of her votes in favor of the hate crimes bill and a version of the Employment Non-Discrimination Act, as well as votes against the Federal Marriage Amendment. Her record was tarnished in May when she voted against an amendment that would lead to repeal of “Don’t Ask, Don’t Tell.”
R. Clarke Cooper, Log Cabin’s national director, noted his organization made the $500 contribution prior to Bono Mack’s vote against “Don’t Ask, Don’t Tell” repeal.
He said although Bono Mack voted against the repeal amendment, she ultimately voted in favor of the fiscal year 2011 defense authorization bill as a whole. Consequently, Cooper said Log Cabin’s endorsement of the Republican lawmaker stands.
“[Log Cabin] will continue to work with Representative Bono Mack,” Cooper said. “Using the carrot approach, additional [Log Cabin] PAC funds could be made available contingent upon her future work and performance in the House.”
Cicilline, who’s running to succeed Rep. Patrick Kennedy (D-R.I.) to represent Rhode Island’s 1st congressional district, meanwhile raised $436,000 in the second quarter. He’s raised $1.16 million over the course of his campaign and ended the quarter with $901,000 in cash on hand.
In a statement provided by his campaign, Cicilline said he’s pleased with his fundraising and the LGBT support he received in the second quarter.
“I am extremely grateful to the members of our community who are supporting my campaign for Congress,” he said. “They are helping to ensure that we have the resources necessary to get our message out for the Sept. 14 primary.”
Bill Lynch, the former head of the Rhode Island Democratic Party who’s running against Cicilline in the primary, raised $55,832 in the second quarter. In the same period, he spent $126,000, leaving him with $139,000 in cash on hand.
The winner of the Democratic primary will likely face Republican John Loughlin, an Iraq war veteran and Rhode Island Assembly member. He raised $104,786 in the second quarter while spending $192,000. Loughlin has $101,000 in cash on hand.
Cicilline is running in a safely Democratic district and the Democratic nominee who wins the primary is widely expected to succeed Kennedy in the U.S. House.
The Providence mayor has been the beneficiary of LGBT support over the course of the campaign, particularly during the second quarter. The Gay & Lesbian Victory Fund, which has endorsed Cicilline, contributed $2,400 to his campaign in the second quarter.
Michael Cole, an HRC spokesperson, said his organization donated $721 to Cicilline in the second quarter, which was mostly in-kind contributions raised through HRC’s website.
Noting that HRC previously donated $6,025 to Cicilline, Cole said HRC plans to max out that contribution to $10,000 by year’s end.
Among the notable contributors to Cicilline’s campaign in the second quarter were Bastian, who donated $4,800; Rosen, who donated $500; Joe Solmonese, HRC’s president, who personally donated $500; and Winnie Stachelberg, senior vice president for external affairs at the Center for American Progress, who donated $1,000.
Other gay congressional candidates seeking office didn’t fare as well as Pougnet or Cicilline during the second quarter.
Ed Potosnak, a gay Democratic former staffer for Rep. Mike Honda (D-Calif.) and public school teacher running in New Jersey, raised $47,000 in the second quarter while spending $26,000.
His finances leave him with $72,000 in cash on hand. Potosnak has raised $148,000 over the course of his campaign. Potosnak’s GOP opponent in his race to represent New Jersey’s 7th congressional district, one-term incumbent Rep. Leonard Lance (R-N.J.), raised $108,000. However, he spent nearly $250,000 in the same period, leaving him with $359,000 in cash on hand.
In what could be an uphill battle for a U.S. House seat, Potosnak is running in a traditionally Republican district. He hasn’t been endorsed by HRC or the Victory Fund.
Despite the funding disparity, Potosnak said he’s happy with the amount he raised in the second quarter because it came from individuals donors and not special interest money.
“Compared to the opponent, the guy that I’m running against, Congressman Lance, I received more contribution from individuals in the last filing — about $5,000 more,” Potosnak said. “I didn’t get the special interest money from the big banks and Wall Street that are fueling his campaign.”
A similar situation with campaign finances is playing out in Florida’s 17th congressional district, where nine candidates, including North Miami City Council member Scott Galvin, are vying for the Democratic nomination in a primary set for Aug. 24.
After raising $57,000 in the second quarter while spending $97,000, Galvin had about $15,000 in cash on hand. He’s raised about $112,000 over the course of his campaign, according to FEC records.
Galvin said he’s feeling good about his finances for the second quarter and was preparing to submit an amended report showing that he has raised $130,000 over the course of his campaign.
“We found several pages of donations that didn’t get included by accident, so for what it’s worth, the to-date total, I guess, would show $130,000,” Galvin said.
The Gay & Lesbian Victory Fund, which has endorsed Galvin, contributed $2,400 to his campaign during the second quarter.
The candidate in the Democratic primary with the greatest war chest is Rudolph Moise, a physician and president of the Comprehensive Health Center in North Miami. He raised $938,162 for his campaign, although $800,000 was a personal loan to his campaign from himself. He spent $280,000 in the second quarter, leaving him with $909,000 in cash on hand.
Galvin said the disparity in finances didn’t bother him and he would remain focused on a “grassroots concentrated effort.”
“We’re doing it through all the old-fashioned, knocking-on-door, mail-to-the-home, traditional way of campaigning,” he said.
The 17th congressional district in Florida is also considered a safely Democratic seat. No Republican candidate has filed for candidacy, so the winner of the Democratic primary would be the presumptive winner of the seat.
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
